Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Polycythemia Vera Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Polycythemia Vera Overview | 8 | 1 |
| Polycythemia Vera Therapeutics under Development by Companies | 9 | 1 |
| Polycythemia Vera Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Polycythemia Vera Products under Development by Companies | 13 | 1 |
| Polycythemia Vera Companies Involved in Therapeutics Development | 14 | 12 |
| ANP Technologies, Inc. | 14 | 1 |
| Bristol-Myers Squibb Company | 15 | 1 |
| F. Hoffmann-La Roche Ltd. | 16 | 1 |
| Galena Biopharma, Inc. | 17 | 1 |
| Gilead Sciences, Inc. | 18 | 1 |
| Italfarmaco S.p.A. | 19 | 1 |
| Karus Therapeutics Limited | 20 | 1 |
| miRagen Therapeutics, Inc. | 21 | 1 |
| Nerviano Medical Sciences S.r.l. | 22 | 1 |
| Novartis AG | 23 | 1 |
| PharmaEssentia Corporation | 24 | 1 |
| Teva Pharmaceutical Industries Ltd. | 25 | 1 |
| Polycythemia Vera Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 41 |
| anagrelide hydrochloride CR Drug Profile | 35 | 3 |
| arsenic trioxide Drug Profile | 38 | 3 |
| dasatinib Drug Profile | 41 | 3 |
| Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia Drug Profile | 44 | 1 |
| givinostat Drug Profile | 45 | 2 |
| idelalisib Drug Profile | 47 | 8 |
| KA-1463 Drug Profile | 55 | 1 |
| M-009 Drug Profile | 56 | 1 |
| M-012 Drug Profile | 57 | 2 |
| MGN-4893 Drug Profile | 59 | 1 |
| momelotinib dihydrochloride Drug Profile | 60 | 5 |
| NMSP-113 Drug Profile | 65 | 1 |
| peginterferon alfa-2a Drug Profile | 66 | 2 |
| ropeginterferon alfa-2b Drug Profile | 68 | 3 |
| sonidegib phosphate Drug Profile | 71 | 5 |
| Polycythemia Vera Dormant Projects | 76 | 1 |
| Polycythemia Vera Discontinued Products | 77 | 1 |
| Polycythemia Vera Product Development Milestones | 78 | 7 |
| Featured News &Press Releases | 78 | 1 |
| May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012 | 78 | 1 |
| May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases | 78 | 1 |
| Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition | 79 | 1 |
| Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition | 80 | 1 |
| Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera | 81 | 1 |
| Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial | 82 | 1 |
| Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera | 82 | 1 |
| Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera | 83 | 1 |
| Feb 17, 2011: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for Treatment of Polycythemia Vera | 84 | 1 |
| Appendix | 85 | 2 |
| Methodology | 85 | 1 |
| Coverage | 85 | 1 |
| Secondary Research | 85 | 1 |
| Primary Research | 85 | 1 |
| Expert Panel Validation | 85 | 1 |
| Contact Us | 85 | 1 |
| Disclaimer | 86 | 1 |